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Until recently, few therapeutic options were available for patients with castration-resistant
prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated beneﬁt
(sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this set-
ting, and to-date several other agents are under investigation in clinical trials. The purpose
of this review is to present an update of targeted therapies for CRPC. Presented data
are obtained from literature and congress reports updated until December 2011. Targeted
therapies in advanced phases of clinical development include novel androgen signaling
inhibitors, inhibitors of alternative signaling pathways, anti-angiogenic agents, inhibitors
that target the bone microenvironment, and immunotherapeutic agents. Radium-223 and
MDV3100 demonstrated a survival advantage in phase III trials and the road for their intro-
duction in clinical practice is rapidly ongoing. Results are also awaited for phase III studies
currently underway or planned with new drugs given as monotherapy (TAK-700, cabozanti-
nib, tasquinimod, PROSTVAC-VF, ipilimumab) or in combination with docetaxel (custirsen,
aﬂibercept, dasatinib, zibotentan). The optimal timing, combination, and sequencing of
emerging therapies remain unknown and require further investigation. Additionally, the
identiﬁcation of novel markers of response and resistance to these therapies may better
individualize treatment for patients with CRPC.
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INTRODUCTION
Prostate cancer (PC) is a major public health problem world-
wide. In recent years an increasing incidence has been reported,
mainly due to both population aging and improvement of diag-
nostic screening. In United States it represents the most com-
mon cancer type and the second cause of cancer death among
men, with about 240,000 estimated new cases and 33,000 esti-
mated deaths in 2011 (Siegel et al., 2011). Different therapeutic
approaches, including surgery, radiation therapy, and androgen
deprivation therapy (ADT) with luteinizing hormone-releasing
hormone (LHRH) analogs and/or antiandrogens,have become the
gold standard treatment for hormone-dependent PC. Chemother-
apy represents, instead, the main therapeutic option in the occur-
rence of castration-resistant PC (CRPC), deﬁned as disease pro-
gressing even in the presence of castration levels of circulating
androgens. In this case, docetaxel 75mg/m2 every 3weeks plus
prednisone 5mg twice daily (BID) represents the standard ﬁrst-
line treatment since 2004,when two phase III trials (Petrylak et al.,
2004; Tannock et al., 2004) showed a prolongation of overall sur-
vival (OS) compared with mitoxantrone. Until 2010, there has
been no standard second-line treatment for patients progress-
ing on docetaxel-based therapy. The expanding knowledge of the
important molecular pathways involved in PC progression has
provided the opportunity to investigate speciﬁc therapeutics for
these patients. Therefore, new therapeutic options have been very
recently introduced into clinical practice, while other emerging
molecules have shown hopeful results. The aim of this review is to
summarize the most important new ﬁndings for metastatic CRPC
(mCRPC) according to the different molecular pathways and to
discuss their potential inﬂuence on future management of this
disease.
NEW APPROVED TREATMENT OPTIONS FOR mCRPC
Thanks to the approval of four innovative molecules by Food
and Drug Administration (FDA) and European Medicines Agency
(EMA), the latest 2 years have marked the beginning of a new
and exciting era for the treatment of mCRPC. Based on phase III
clinical trials (De Bono et al., 2010, 2011; Kantoff et al., 2010a;
Fizazi et al., 2011) cabazitaxel, abiraterone acetate, sipuleucel-T,
and denosumab represent available therapeutic options in this
setting. Cabazitaxel is a tubulin binding agent with weak afﬁnity
forP-glycoprotein (Bouchet andGalmarini, 2010). Following data
from the TROPIC trial, which showed an OS beneﬁt in patients
treated with cabazitaxel 25mg/m2 every 3weeks versus standard
mitoxantrone after docetaxel failure (De Bono et al., 2010), FDA
on June 2010 and EMA on January 2011 approved this treatment
for mCRPC. Two ongoing trials (FIRSTANA and PROSELICA),
are now being evaluated two different doses (20 and 25mg/m2)
in pre- and post-docetaxel settings to assess if dose reduction,
often required because of myelotoxicity, could affect therapeutic
response. The mechanism of action of taxanes seems to involve
not only microtubule stabilization and tubulin function, but also
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both androgen receptor (AR) nuclear localization and signaling
inhibition (Gan et al., 2009; Jiang and Huang, 2010). This interac-
tion may lead to a more complex and successful inhibition of cell
growth, as it has been demonstrated that AR signaling is main-
tained in CRPC and is implicated in its progression (Attar et al.,
2009). Evidence of persistent hormone dependence inmCRPChas
opened the way to the development of new antiandrogens able to
block testosterone synthesis not only by testes, but also by adrenal
glands and prostate tumor tissue. Abiraterone acetate is an oral,
selective, and irreversible inhibitor of CYP17, a critical enzyme in
androgen biosynthesis, which blocks non-gonadal androgen pro-
duction. Abiraterone at a dose of 1000mg/day in combination
with prednisone 10mg/day was approved by FDA on April 2011
and by EMA on July 2011 for the treatment of mCRPC after a
docetaxel chemotherapy following the results of the COU-AA-301
trial, which demonstrated a survival beneﬁt for the experimental
arm compared with placebo (De Bono et al., 2011). A similar
placebo-controlled phase III trial (COU-AA-302) evaluating abi-
raterone in docetaxel-naïve patients progressing after ADT has
completed accrual and will provide data about the use of this drug
before chemotherapy.
Sipuleucel-T is obtained by activating patient’s leukapheresed
antigen-presenting cells (APCs), including dendritic cells, with
a recombinant fusion protein consisting of prostatic acid phos-
phatase (PAP) antigen and granulocyte-macrophage colony-
stimulating factor (GM-CSF), an immune-cell activator. This cel-
lular immunotherapy produced an advantage in terms of OS in
the IMPACT study, a placebo-controlled phase III trial that led,
on April 2010, to the FDA approval in patients with asympto-
matic or minimally symptomatic mCRPC (Kantoff et al., 2010a).
It will be important to evaluate the rational combination and
proper sequencing of sipuleucel-T with these newly approved,
as well as emerging (MDV3100, TAK-700, ipilimumab) agents
(Sonpavde et al., 2012).
Finally, denosumab, a human monoclonal antibody against
receptor activator of nuclear factor-kappa ligand (RANK-L),
showed superiority in preventing skeletal-related events (SREs)
versus zoledronic acid in patients with bone metastases from
CRPC (Fizazi et al., 2011) and breast cancer (Stopeck et al., 2010),
and non-inferiority in patients with other solid tumors, exclud-
ing multiple myeloma (Henry et al., 2011). It has therefore been
approved by FDA and EMA for the prevention of SREs in patients
withmetastatic bone disease. In addition, denosumabwas demon-
strated to delay the time to ﬁrst bone metastasis and to increase
bone-metastasis-free survival (BMFS) in men with non-mCRPC
at high risk of bone metastasis (Smith et al., 2012), conﬁrming its
potential clinical role.
TARGETING THE ANDROGEN RECEPTOR PATHWAY
SPECIFIC CYP17 INHIBITOR: TAK-700
TAK-700 (orteronel) is an oral, selective, reversible, non-steroidal
androgen synthesis inhibitor of the 17.20 lyase activity, one of two
enzymatic reactions catalyzed by CYP17. Due to its low inhibi-
tion of 17-hydroxylase activity, administration does not require
concomitant steroid replacement (Ryan and Tindall, 2011). This
compound showed activity and good tolerability in a phase I/II
clinical trial on chemotherapy naïve patients (Agus et al., 2011;
Mortimer et al., 2011). Phase I patients received TAK-700 escalat-
ing doses (100–600mg BID), while phase II ones were given TAK-
700 300mg BID, 600mg once daily (QD), or two dose levels (400
or 600mg BID) plus prednisone 5mg BID. In the phase II portion,
97 patients received TAK-700. Most common adverse events (AEs)
were fatigue (72%), nausea (44%), and constipation (31%), with
fatigue (9%) and diarrhea (3%) as most common grade ≥3 AEs.
TAK-700 resulted in reduced circulating testosterone and adrenal
androgen dehydroepiandrosterone sulfate (DHEA-S) concentra-
tions. Of 43 RECIST-evaluable patients, 6 had a partial response
(PR), 23 had stable disease (SD), and 9 had progression disease
(PD). PSA response rates (≥50% decrease) at 12weeks were sim-
ilar across treatment groups, with an overall response rate (ORR)
of 53%. Researchers concluded that, in patients with mCRPC, oral
TAK-700 (with/without prednisone) at doses of ≥300mg BID
was active and well tolerated. Based on these positive ﬁndings, two
randomized, phase III, placebo-controlled multicenter studies are
currently being investigated efﬁcacy and safety of TAK-700 400mg
BID plus prednisone 5mg BID versus placebo plus prednisone in
chemotherapy naïve and docetaxel-pre-treated mCRPC patients.
NEW AR ANTAGONISTS
Ligand-independent continued activation of ARs is one of the
mechanisms that allow PC cells to survive and grow in the pres-
ence of castrate androgen levels. Receptor mutations (Taplin et al.,
2003), alternative splicingwith synthesis of AR splice variants (Sun
et al., 2010), AR encoding gene ampliﬁcation (Liu et al., 2009) as
well as co-activators dysregulation have been described as poten-
tial escape mechanisms implicated in CRPC progression. First-
generation AR antagonists, such as bicalutamide or ﬂutamide,
represent the standard of care for advanced PC since the eighties.
However, they bind reversibly to ARs and may have androgen-
agonist properties, as demonstrated in cells engineered to over-
express higherAR amounts (Tran et al., 2009), limiting therapeutic
activity. This has raised the need to develop more potent and
efﬁcacious molecules. In such a perspective, new antiandrogens
with improved binding properties have been produced. One of
these agents, MDV3100, is an oral AR antagonist small mole-
cule that binds to ARs with higher afﬁnity than bicalutamide,
blocking AR nuclear translocation, co-activators recruitment, and
DNA binding without agonist activity when AR is overexpressed
(Tran et al., 2009). Unlike bicalutamide, MDV3100 do not induce
expression of the AR target genes PSA and transmembrane ser-
ine protease 2 (TMPRSS2) in a pre-clinical model, indicating the
absence of agonist activity in a castration-resistant setting (Tran
et al., 2009). MDV3100 has demonstrated a promising clinical
activity in CRPC in a phase I/II trial (Scher et al., 2010) evaluating
drug escalating doses (from 30 to 600mg/day) on 140 patients, 65
chemotherapy naïve and 75 previously treated with docetaxel. A
recent update (Higano et al., 2011) after a long-term follow-up on
time to PSA and radiographic progression, conﬁrmed a durable
anti-tumor activity of MDV3100. The median time to PSA pro-
gression, deﬁned per-protocol as a ≥25% increase in PSA from
baseline,was notmet for naïve patients andwas 8months for post-
chemotherapy patients. Themedian time to radiographic progres-
sionwas 13months for naïve and6months for post-chemotherapy
group.MDV3100was generally well tolerated,with fatigue asmost
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frequently reported AE (Scher et al., 2010). Based on these inter-
esting results, MDV3100 is currently being evaluated in two phase
III studies, in pre- (PREVAIL) and post-docetaxel (AFFIRM) set-
tings. AFFIRM is a randomized, placebo-controlled, double-blind,
multi-national trial evaluating MDV3100 160mg/day in mCRPC
men previously treated with docetaxel-based chemotherapy. The
primary endpoint isOS, secondary endpoints includeprogression-
free survival (PFS), safety, and tolerability. OnNovember 2011, the
results of a planned interim analysis performed by the Indepen-
dentDataMonitoringCommittee (IDMC) showed thatMDV3100
produced a 4.8-month advantage in median OS compared to
placebo (18.4months for MDV3100 versus 13.6 for placebo), with
a 37% (HR= 0.631) reduction in the risk of death in the treated
population. Consequently, IDMC recommended AFFIRM early
stop, and men given placebo were offered MDV3100. A full analy-
sis of the results from AFFIRM including safety data will be soon
presented.ARN-509 is a novel smallmoleculeARantagonistwith a
mechanism of action similar to that of MDV3100, which showed
powerful anti-cancer activity and induced durable remission in
advanced CRPC mouse models. It seems to produce higher rates
and longer duration of responses than MDV3100. An ongoing
phase I/II clinical trial of continuous oral ARN-509 in patients
with progressive CRPC with and without prior chemotherapy was
started in July 2010 (Rathkopf et al., 2011a). Finally, AZD3514, a
selective AR degrading and down-regulating agent, orally avail-
able, given on a daily continuous schedule, is now being tested in
a phase I clinical trial, with an estimated completion date of 2013.
DUAL CYP17 INHIBITOR AND AR ANTAGONIST: TOK-001
Some of the CYP17 inhibitors are of particular interest as they are
also AR antagonists and cause receptor down-regulation. TOK-
001 (VN/124-1) is the ﬁrst compound to show superior efﬁcacy
compared with castration in PC xenograft models (Handratta
et al., 2005). It also inhibits the proliferation of hormone-resistant
PC cell lines (HP-LNCaP), which are no longer sensitive to bica-
lutamide and have an increased AR expression (Schayowitz et al.,
2008). These impressive pre-clinical data led to the development
of this compound in the clinical setting. The results of the phase
I/II clinical trial ARMOR1, conducted in treatment-naïve CRPC
patients progressing on ADT, are awaited after its completion in
July 2012.
TARGETING NON-HORMONAL INTRACELLULAR MOLECULAR
PATHWAYS
SIGNAL TRANSDUCTION PATHWAYS INHIBITORS
There is growing evidence indicating the presence of signaling
mechanisms and cross-talk between growth factor receptor path-
ways and AR in androgen-dependent and hormone-resistant PC
cell lines (Schayowitz et al., 2008), that lead to AR regulation by
signal transduction pathways and vice versa (Traish and Morgen-
taler, 2009). Cross-talk between AR and growth factor pathways
may represent a key factor during PC progression, conferring a
survival, and invasion advantage to tumor cells, together with a
resistance to hormonal therapy. This mutual relationship involves
epidermal growth factor receptors (EGFRandHER-2), insulin-like
growth factor receptor (IGFR), ﬁbroblast growth factor recep-
tor (FGFR), vascular endothelial growth factor (VEGF) receptor
(VEGFR), transforming growth factor-β (TGFβ), phosphoinosi-
tide 3-kinase (PI3-K), Akt, and mammalian target of rapamycin
(mTOR) pathways (Wen et al., 2000; Manin et al., 2002; Zhu and
Kyprianou, 2008) and represents a potential target to overcome
endocrine resistance. Drugs targeting EGFR and/or HER-2 did
not produce signiﬁcant results in CRPC (Boccardo et al., 2008;
Nabhan et al., 2009; Slovin et al., 2009a; Whang et al., 2011), while
mTOR inhibitors seemed to have some activity. In particular, in
pre-clinical studies on cellular (Schayowitz et al., 2008;Wedel et al.,
2011) and xenograft models (Morgan et al., 2008; Schayowitz
et al., 2010) everolimus demonstrated positive results in com-
bination with TOK-001 (Schayowitz et al., 2008, 2010), AEE788
(a dual VEGFR/EGFR inhibitor; Wedel et al., 2011), and doc-
etaxel plus zoledronic acid (Morgan et al., 2008). A phase II study
(Templeton et al., 2011) investigating the activity of everolimus
10mg/daily as ﬁrst-line treatment in patients with mCRPC has
been recently presented. Among 37 enrolled patients, 12 (32%)
remained progression-free at 12weeks. Other phase II studies of
everolimus, alone or in combination with bicalutamide, beva-
cizumab, or chemotherapy, as well as trials testing other mTOR
inhibitors such as temsirolimus and ridaforolimus, are currently
recruiting patients. IGF-1R inhibitors are also being evaluated in
CRPC. Among these, cixutumumab (IMC-A12), a monoclonal
antibody, is under study in a phase I/II trial in combination
with temsirolimus in chemo-naïve mCRPC patients. The study
has completed phase I accrual and early results have shown good
tolerability (Rathkopf et al., 2011b).
INHIBITORS OF SURVIVAL FACTORS
Overexpression of proteins belonging to inhibitor of apoptosis
(IAP) family, like Bcl-2, Bcl-X, survivin, and Mcl-1 (Raffo et al.,
1995; Krajewska et al., 1996; Zhang et al., 2005), or of the stress-
induced cytoprotective chaperone protein clusterin (Shiota et al.,
2011) inPCcells is associatedwithdisease progression,cell survival
advantage, and resistance to ADT and chemotherapy-mediated
apoptosis. Oblimersen, an anti-Bcl-2 antisense oligonucleotide
(Sternberg et al., 2009), and AT-101, a small molecule inhibitor of
the Bcl-2 family (Sonpavde et al., 2011), were studied as ﬁrst-line
treatment forCRPC in combinationwithdocetaxel.However, clin-
ical results were both negative in terms of PSA response and OS.
Similarly,YM155, a smallmolecule suppressor of survivin, showed
modest activity in taxane-pre-treated CRPC patients (Tolcher
et al., 2012).
Custirsen (OGX-011) is an antisense oligonucleotide comple-
mentary to clusterin mRNA that inhibits its translation. In a
randomized phase II trial (Chi et al., 2010) custirsen 640mg intra-
venously weekly plus standard docetaxel as ﬁrst-line treatment
improved median OS in CRPC patients compared with docetaxel
alone (23.8 versus 16.9months), even if PSA and tumor response
rates were similar. Another phase II trial tested custirsen in com-
bination with mitoxantrone or docetaxel treatment as second-line
therapy after progression during or within 6months of initial
docetaxel therapy (Saad et al., 2011). Pain relief was observed
in 46 and 77% of patients, respectively. These rates were higher
than expected, with interesting correlations between serum clus-
terin and survival. Two phase III studies are ongoing: SYNERGY,
planned to enroll 800 patients, which will conﬁrm whether adding
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custirsen to standard ﬁrst-line docetaxel treatment slows tumor
progression and enhances survival compared to chemotherapy
alone, and SATURN, investigating custirsen in association with
docetaxel as second-line retreatment.
DUAL c-MET/VEGFR2 INHIBITOR: CABOZANTINIB
As known, the hepatocyte growth factor/scatter factor (HGF/SF)
and its receptor, the tyrosine kinase c-MET, promote tumor
growth, invasion, and metastasis in several malignancies (Birch-
meier et al., 2003). In PC, c-MET expression was demonstrated
to be repressed by AR (Verras et al., 2007), with a consequent
enhanced synthesis duringADT and in the hormone-independent
state. Moreover, c-MET pathway activation is associated with pro-
gression to bone (Knudsen et al., 2002), and seems to induce a
stem-like phenotype (Van Leenders et al., 2011) conferring a high
invasive capacity, especially in the perimeter of prostate tumor,
where this proto-oncogene is more expressed.
Cabozantinib (XL184) is an oral small molecule inhibitor of
multiple kinase signalingpathways including c-METandVEGFR2.
An interim analysis of a phase II study, designed as a “randomized
discontinuation” trial in patients with mCRPC, was recently pre-
sented (Hussain et al., 2011). After 12weeks of treatment, patients
with PR continued open-label cabozantinib, those with SD were
blindly randomized to cabozantinib versus placebo, and those
with PD discontinued treatment. Cabozantinib 100mg/day led
to improvement of bone parameters, especially bone scan and
markers, as early as week 6. At this time, among bone evaluable
patients, 86% complete or partial resolution of bone metastases
and 12% stabilizations were reported. Prolonged PFS (21 versus
6weeks) was registered in the cohort of patients undergone ran-
domization. At week 12 disease control rate (PR+ SD) was 71%
with fatigue, hypertension, and hand-foot syndrome as major
AEs. Based on this early clinical activity, two phase III trials are
planned to test cabozantinib 60mg/daily in patients with mCRPC
after treatment with docetaxel and abiraterone: the 306 trial with
mitoxantrone/prednisone as control arm and relief of bone pain
as primary endpoint, and the 307 trial, comparing cabozantinib
versus prednisone with OS as primary endpoint.
TARGETING ANGIOGENESIS
Angiogenesis and VEGFR pathway play a key role in CRPC pro-
gression and metastasis (Sweeney et al., 2002; Tomic et al., 2012),
as in the majority of cancers and thus several anti-angiogenic
drugs are currently studied in this setting. Bevacizumab, a human-
ized monoclonal antibody against VEGF, was evaluated in vari-
ous phase II clinical trials in combination with docetaxel, either
monotherapy or associated with other agents such as thalidomide,
estramustine (Di Lorenzo et al., 2008; Ning et al., 2010; Picus et al.,
2011), or lenalidomide (Huang et al., 2011), showing anti-tumor
activity. Nevertheless, the phase III CALGB 90401 study (Kelly et
al., 2010) failed to obtain OS advantage, and important morbidity
and mortality rates were seen.
Lenalidomide is an angiogenesis inhibitor similar to thalido-
mide with immune-modulatory effects, which was tested in the
MAINSAIL, a pivotal double-blinded phase III trial designed to
evaluate the efﬁcacy and safety of docetaxel and prednisone with
or without lenalidomide in CRPC patients. In November 2011,
Celgene International Sàrl announced studydiscontinuation, since
the combination treatment would not demonstrate a statistically
signiﬁcant effect.
Aﬂibercept is a promising anti-VEGF agent, also called VEGF-
trap (Lockhart et al., 2010). It is a recombinant protein consisting
of the Fc portion of human IgG1 combined with the extracellu-
lar ligand-binding domains 2 and 3 of the human VEGFR 1 and
2, now under investigation in the phase III VENICE trial. This
study, testing aﬂibercept in combination with ﬁrst-line docetaxel,
has completed accrual and results are awaited.
Tasquinimod is an oral quinoline-3 carboxamide derivative
with a new anti-angiogenic and anti-tumor activity. It binds
to S100A9 (Björk et al., 2009), an immune-modulatory protein
expressed on myeloid-derived suppressor cells (MDSCs), impor-
tant tumor microenvironment mediators of angiogenesis and
tumor growth (Schmid and Varner, 2010). In a randomized pre-
chemotherapy placebo-controlled phase II trial, an improved PFS
(7.6 versus 3.3months) was seen in patients in tasquinimod arm
(Pili et al., 2011). Most frequent AEs recorded in tasquinimod
group included gastrointestinal disorders, fatigue,musculoskeletal
pains, and elevations of pancreatic and inﬂammatory biomark-
ers. A phase III placebo-controlled study is ongoing in a larger
pre-docetaxel mCRPC population.
Given encouraging results in several phase II trials (Dror
Michaelson et al., 2009; Sonpavde et al., 2010; Zurita et al., 2012),
themulti-tyrosine kinase inhibitor and anti-angiogenic smallmol-
ecule sunitinib was investigated in a phase III trial (SUN1120)
with OS as primary endpoint in patients with progressive mCRPC
after docetaxel-based chemotherapy (Michaelson et al., 2011).
Nevertheless, the study was stopped for futility at the second
interim analysis on September 2010. Many other drugs target-
ing angiogenesis are in clinical development for CRPC, including
the multi-kinase inhibitor sorafenib active against c-raf, BRAF,
VEGFR, platelet-derived growth factor receptor, Flt-3, c-KIT, and
RET. Sorafenib showed contrasting results in phase II studies,
due to discordant imaging and PSA responses (Steinbild et al.,
2007; Chi et al., 2008; Aragon-Ching et al., 2009), therefore further
evaluations are needed.
TARGETING THE BONE MICROENVIRONMENT
Src-FAMILY KINASES INHIBITORS
Src and Src-family kinases (SFKs) are a family of intracellular
tyrosine kinases that mediate transduction of several molecu-
lar pathways implicated in PC growth, invasion, and progres-
sion (Tatarov et al., 2009). Src signaling is also involved in the
development of bone metastasis, as it regulates different osteo-
clast functions including bone resorption (Miyazaki et al., 2004).
Dasatinib is a SFK and Abl kinase inhibitor able to suppress PC
cells-induced osteoclast differentiation and activity in pre-clinical
models (Araujo et al., 2009;Vandyke et al., 2010). Itwas studied in a
phase II trial (Yu et al., 2009) conducted in 47 chemotherapy naïve
men with CRPC and biochemical progression. Patients were given
dasatinib 100 or 70mg BID. Both these schedules demonstrated
biologic activity, especially on bone turnovermarkers, but remark-
able AEs including diarrhea (62% of patients), pleural (51%), and
pericardial (23%) effusions were recorded. The trial was amended
because of toxicity and an expansion cohort of 48 patients was
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treated with dasatinib 100mg once daily (Yu et al., 2011). At
this dose the drug conﬁrmed a good clinical activity and had a
better tolerability proﬁle with lesser grade 3/4 AEs (13% versus
32%), particularly 19% versus 51% pleural effusions, compared
with the BID dosage. Dasatinib in combination with docetaxel has
been studied in a recently published phase I/II trial (Araujo et al.,
2012). Of 46 treated patients, 37 (80%) had any PSA decrease,
including 26 (57%) who had a conﬁrmed PSA response. Among
RECIST-evaluable patients, 18 of 30 (60%) had PR with a 77% of
overall disease control rate (PR+ SD). Parallel bone scan improve-
ments and urinary bone resorption markers decline were also
observed. The combination was well tolerated, with a decreased
frequency of pleural effusion (15%), probably due to the con-
comitant prednisone administration. READY, a phase III trial
of docetaxel with or without dasatinib as ﬁrst-line treatment of
mCRPC is now ongoing. Another SFK inhibitor in clinical devel-
opment for PC, saracatinib (AZD0530), showed limited clinical
efﬁcacy as monotherapy in a phase II trial (Lara et al., 2009).
ENDOTHELIN-1 RECEPTOR ANTAGONISTS
Thepathogenesis of osteoblastic bonemetastasis,which frequently
occur in mCRPC, is characterized by dysregulation of both bone
resorption and formation (Guise et al., 2006). In particular, a role
has been identiﬁed for the vasoactive peptide endothelin-1 (ET-
1), produced by metastatic cancer cells in the microenvironment
of new-formed bone, through the stimulation of the endothelin
A receptor (ETaR) and its downstream pathways in osteoblastic
cells (Yin et al., 2003). Atrasentan (ABT-627), an ETaR antagonist,
reduced osteoblastic bone metastases, and bone tumor burden
in in vitro and in vivo pre-clinical models (Yin et al., 2003),
demonstrating an additive anti-tumor effect in combination with
taxanes (Akhavan et al., 2006; Banerjee et al., 2007). Despite pos-
itive effects of atrasentan monotherapy in delaying median time
to disease and PSA progression, as observed in a double-blinded,
randomized, placebo-controlled phase II clinical trial (Carducci
et al., 2003), data from two phase III studies carried out with this
agent in either non-metastatic or metastatic disease failed to show
a signiﬁcant beneﬁt in time to progression (Carducci et al., 2007;
Nelson et al., 2008). Similarly, the phase III SWOG 0421 trial of
atrasentan plus docetaxel as ﬁrst-line therapy was closed early due
to failure in reaching the primary endpoints (OS and PFS). Also
zibotentan (ZD4054), another ETaR antagonist, presented discor-
dant data among a phase II trial (James et al., 2010) and two of the
subsequent phase III trials. The ENTHUSE clinical trial program
consists of three phase III clinical studies designed to evaluate zibo-
tentan monotherapy in men with metastatic (ENTHUSE M1 trial
14) and non-metastatic (ENTHUSE M0 trial 15) CRPC, as well as
its combination with docetaxel as ﬁrst-line treatment (ENTHUSE
M1C trial 33). Both ENTHUSE studies 14 (Nelson et al., 2011) and
15 (not published) were stopped following the negative results to
meet primary efﬁcacy endpoints, while ENTHUSE study 33 will
be continued and full results are expected.
RADIOPHARMACEUTICALS
Unlike strontium-89 and samarium-153,beta-emitting radiophar-
maceuticals approved for palliation of bone metastasis-related
pain (National Comprehensive Cancer Network (NCCN), 2011),
radium-223 (alpharadin) targets bone metastasis with higher
energy and shorter track length alpha-radiation. This allows
hematopoietic bone marrow cells to be partly spared from damage
Table 1 | Positive phase III trials with emerging therapies for CRPC.
Clinical trial Target Experimental
versus control
Population Primary
endpoint
Outcome
TROPIC
NCT00417079
Microtubules
and tubulin
Cabazitaxel+P versus
mitoxantrone+P
Docetaxel pre-treated
mCRPC
OS Improved OS (15.1 versus 12.7months;
HR=0.70)
COU-AA-301
NCT00638690
CYP 17 Abiraterone acetate+P
versus placebo+P
Docetaxel pre-treated
mCRPC
OS Improved OS (14.8 versus 10.9months;
HR=0.646)
IMPACT
NCT00065442
Anti-tumor
immune
response
Sipuleucel-T versus placebo Asymptomatic or minimally
symptomatic mCRPC
OS Improved OS (25.8 versus 21.7months;
HR=0.775)
20050103
NCT00321620
RANK-L Denosumab+placebo versus
zoledronic ac+placebo
Bone metastatic CRPC Time to
ﬁrst SRE
Improved time to ﬁrst SRE (20.7 versus
17.1months; HR=0.82)
‘147TRIAL
NCT00286091
RANK-L Denosumab versus placebo CRPC without bone
metastases
BMFS Improved BMFS (29.5 versus
25.2months; HR=0.85)
AFFIRM
NCT00974311
Androgen
receptor
MDV3100 versus placebo Docetaxel pre-treated
mCRPC
OS Improved OS (18.4 versus 13.6months;
HR=0.631)
ALSYMPCA
NCT00699751
Bone microen-
vironment
Radium-223 versus placebo Bone metastatic
symptomatic CRPC
OS Improved OS (14.0 versus 11.2months;
HR=0.699)
CRPC, castration-resistant prostate cancer; P, prednisone; OS, overall survival; RANK-L, receptor activator of nuclear factor-kappa ligand; SRE, skeletal-related event;
BMFS, bone metastases-free survival.
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due to radiation (Nilsson et al., 2007). A phase II trial reported
minimum myelotoxicity and a signiﬁcant effect on bone-alkaline
phosphatase concentrations in patients treated with radium-223
versus placebo (Nilsson et al., 2007). The subsequent phase III
ALSYMPCA trialwas prematurely stopped in June 2011 after a pre-
planned interim efﬁcacy analysis showing a signiﬁcant 2.8-month
OS beneﬁt in the radium-223 armover placebo arm (HR= 0.699).
Based on these results approval procedures are ongoing.
IMMUNOTHERAPY
In addition to sipuleucel-T, further immunotherapeutic strategies
are being exploredwith the aim to induce a speciﬁc T-cell response
against PC (Gerritsen and Sharma,2012).However expensive costs
and complex procedures represent limiting factors for the applica-
tion of these new options in clinical practice. Updated results of a
phase II study of a PSA-targeted poxviral vaccine, PROSTVAC-VF
(rV-PSA), for patients with mCRPC, reported a 44% reduction
Table 2 | Ongoing phase III trials with emerging targeted therapies for CRPC.
Clinical trial Target Experimental
versus control
Population Primary
endpoint
Outcome
COU-AA-302
NCT00887198
CYP 17 Abiraterone acetate+P
versus placebo+P
Chemotherapy naïve mCRPC OS, PFS Ongoing
C21005 NCT01193257 CYP 17, 17.20 lyase activity TAK-700+P versus
placebo+P
Docetaxel pre-treated mCRPC OS Ongoing
C21004 NCT01193244 CYP 17, 17.20 lyase activity TAK-700+P versus
placebo+P
Chemotherapy naïve mCRPC OS, rPFS Ongoing
PREVAIL NCT01212991 Androgen receptor MDV3100 versus placebo Chemotherapy naïve mCRPC OS, PFS Ongoing
SATURN NCT01083615 Clusterin mRNA Custirsen+D+P versus
placebo+D+P
Docetaxel pre-treated mCRPC Pain palliation Ongoing
SYNERGY
NCT01188187
Clusterin mRNA Custirsen+D+P versus
placebo+D+P
Chemotherapy naïve mCRPC OS Ongoing
‘306TRIAL c-MET and VEGFR2 Cabozantinib versus
mitoxantrone+P
Docetaxel-abiraterone
pre-treated mCRPC
Bone pain
alleviation
Planned
‘307TRIAL c-MET and VEGFR2 Cabozantinib versus P Docetaxel-abiraterone
pre-treated mCRPC
OS Planned
VENICE NCT00519285 VEGFA, VEGFB, PIGF Aﬂibercept+D+P versus
placebo+D+P
Chemotherapy naïve mCRPC OS Ongoing
NCT0123431 Immune-modulatory
protein S100A9
Tasquinimod versus placebo Asymptomatic or minimally
symptomatic Docetaxel
pre-treated mCRPC
PFS Ongoing
READY NCT00744497 Src and Src-family kinases Dasatinib+D+P versus
placebo+D+P
Chemotherapy naïve mCRPC OS Ongoing
ENTHUSE M1C (33)
NCT00617669
Endothelin A receptor Zibotentan+D+P versus
placebo+D+P
Chemotherapy naïve mCRPC OS Ongoing
PROSPECT
NCT01322490
Anti-tumor immune
response
PROSTVAC±GM-CSF versus
placebo
Asymptomatic or minimally
symptomatic chemotherapy
naïve mCRPC
OS Ongoing
CA-184-043
NCT00861614
CTLA-4 Ipilimumab versus placebo,
following a single dose of
radiotherapy
Docetaxel pre-treated mCRPC OS Ongoing
CA-184-095
NCT01057810
CTLA-4 Ipilimumab versus placebo Asymptomatic or minimally
symptomatic chemotherapy
naïve mCRPC
OS Ongoing
CRPC, castration-resistant prostate cancer; P, prednisone; OS, overall survival; PFS, progression-free survival; rPFS, radiographic progression-free survival; D, doc-
etaxel; VEGFR, vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor; PIGF, placental growth factor; GM-CSF, granulocyte-macrophage
colony-stimulating factor; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4.
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Table 3 | Negative phase III trials with emerging targeted therapies for CRPC.
Clinical trial Target Experimental
versus control
Population Primary
endpoint
Outcome
CALGB 90401
NCT00110214
VEGFA Bevacizumab+D+P
versus placebo+D+P
Chemotherapy naïve
mCRPC
OS Improved PFS (9.9 versus
7.5months) but not OS
MAINSAIL
NCT00988208
Angiogenesis, immune
cells
Lenalidomide+D+P
versus placebo+D+P
Chemotherapy naïve
mCRPC
OS Discontinued in November
2011 for futility
SUN1120
NCT00676650
VEGFR1/2, PDGFR,
c-KIT, RET
Sunitinib+P versus
placebo+P
Docetaxel pre-treated
mCRPC
OS Discontinued in September
2010 for futility
SWOG 0421
NCT00134056
Endothelin A receptor Atrasentan+D+P
versus placebo+D+P
Chemotherapy naïve
mCRPC
OS, PFS Closed early for futility
ENTHUSE M1 Study 14
NCT00554229
Endothelin A receptor Zibotentan versus
placebo
Bone metastatic CRPC,
mild pain, or no pain
OS Closed early for futility
ENTHUSE M0 Study 15
NCT00626548
Endothelin A receptor Zibotentan versus
placebo
Non-metastatic CRPC OS, PFS Discontinued in February 2011
for futility
VITAL-1 NCT00089856 Anti-tumor immune
response
GVAX versus D+P Asymptomatic
chemotherapy naïve
mCRPC
OS Closed early for futility
VITAL-2 NCT00133224 Anti-tumor immune
response
GVAX+D versus D+P Symptomatic
chemotherapy naïve
mCRPC
OS Discontinued early for
increased deaths in the GVAX
arm
CRPC, castration-resistant prostate cancer; VEGF, vascular endothelial growth factor; D, docetaxel; P, prednisone; OS, overall survival; PFS, progression-free survival;
VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor.
in the death rate, and an 8.5-month improvement in median OS
despite a similar PFS (Kantoff et al., 2010b). To conﬁrm these pos-
itive data, the phase III study PROSPECT was recently initiated in
patients with asymptomatic or minimally symptomatic mCRPC.
GVAX is a cell-based vaccine consisting of LNCaP and PC-3
prostate cell lines, genetically engineered to secrete high levels of
GM-CSF. These cells are injected intradermally in order to ini-
tiate an antiprostate immune response (Gerritsen and Sharma,
2012). Despite promising results of a phase II study (Higano et al.,
2008), two phase III clinical trials, VITAL-1 and 2, were both
terminated early due to futility (VITAL-1) and increased death
rates (VITAL-2) in the GVAX arms (Small et al., 2009). The fully
human antibody ipilimumab blocks a negative regulator of T cells,
the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), lead-
ing to an increased anti-tumor immune response. Early results
of phase I/II clinical trials testing ipilimumab alone (Small et al.,
2007) and in combination with GM-CSF (Fong et al., 2009) or
radiotherapy (Slovin et al., 2009b) showed some activity. There-
fore, two phase III placebo-controlled trials are being evaluated
ipilimumab in CRPC patients either following radiotherapy after
docetaxel chemotherapy or in chemo-naïve patients.
CONCLUSION
Prostate cancer management scenario is rapidly evolving thanks to
the already approved and the emerging therapies in clinical devel-
opment. Among new agents studied in phase III trials, cabazitaxel,
abiraterone acetate, sipuleucel-T,MDV3100, and radium-223 have
shown signiﬁcant OS advantages, while denosumab has delayed
time to ﬁrst SRE and prolonged BMFS (Table 1). Therefore, these
drugs have been or are going to be approved into clinical prac-
tice. Other agents are still under investigation in phase III trials
and results are pending (Table 2). Among them, cabozantinib,
custirsen, and dasatinib seem to be the most promising. However,
even if all trials listed on Table 1 show positive results, they are not
comparable because of heterogeneous study populations and con-
trol arms (i.e., cabazitaxel was tested versus mitoxantrone, other
agents versus placebo). Further studies directly comparing these
compounds are thus needed to better evaluate their clinical activ-
ity. Moreover, failure of various clinical trials testing treatment
options for mCRPC (Table 3) reveals the complexity of research in
this ﬁeld and the related open questions. Firstly,while on one hand
the availability of several novel compounds represents a mean-
ingful tool against CRPC, on the other hand the use of multiple
therapeutic strategies in these patientsmay confound study results,
especially when OS is chosen as primary endpoint. This aspect
should be taken into account when clinical trials are designed for
this setting. Secondly, optimal timing, proper combination, and
sequencing of the different therapeutic approaches need to be
better deﬁned. In fact, as the majority of innovative drugs have
been tested in advanced stages of disease, it would be important
to evaluate whether their earlier use could improve the outcomes.
Moreover, until now clinical trials have been conducted in unse-
lected populations, without regard on tumor genomic signature
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and molecular expression. In the near future, identiﬁcation of dif-
ferent PC molecular subtypes through genomic and/or proteomic
analyses, as well as prognostic and predictive markers, will allow
us to exploit the potential differences in disease biology, in order
to optimize therapy for each PC patient with individualized and
more efﬁcacious treatments.
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